AU2015301952B2 - Oral composition for delivery of drugs and other substances - Google Patents

Oral composition for delivery of drugs and other substances Download PDF

Info

Publication number
AU2015301952B2
AU2015301952B2 AU2015301952A AU2015301952A AU2015301952B2 AU 2015301952 B2 AU2015301952 B2 AU 2015301952B2 AU 2015301952 A AU2015301952 A AU 2015301952A AU 2015301952 A AU2015301952 A AU 2015301952A AU 2015301952 B2 AU2015301952 B2 AU 2015301952B2
Authority
AU
Australia
Prior art keywords
composition
general formula
monoglyceride
fatty acid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301952A
Other languages
English (en)
Other versions
AU2015301952A1 (en
Inventor
Stephen W. Burgess
Shengrong LI
Walter Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanti Polar Lipids Inc
Original Assignee
Avanti Polar Lipids Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Polar Lipids Inc filed Critical Avanti Polar Lipids Inc
Publication of AU2015301952A1 publication Critical patent/AU2015301952A1/en
Application granted granted Critical
Publication of AU2015301952B2 publication Critical patent/AU2015301952B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015301952A 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances Active AU2015301952B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035393P 2014-08-09 2014-08-09
US62/035,393 2014-08-09
PCT/US2015/044501 WO2016025401A1 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Publications (2)

Publication Number Publication Date
AU2015301952A1 AU2015301952A1 (en) 2017-02-16
AU2015301952B2 true AU2015301952B2 (en) 2020-12-03

Family

ID=55304531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301952A Active AU2015301952B2 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Country Status (11)

Country Link
US (3) US9872908B2 (enExample)
EP (1) EP3177279B1 (enExample)
JP (1) JP6759203B2 (enExample)
KR (2) KR102507657B1 (enExample)
CN (1) CN107072967B (enExample)
AU (1) AU2015301952B2 (enExample)
CA (1) CA2956960C (enExample)
DK (1) DK3177279T3 (enExample)
ES (1) ES3033965T3 (enExample)
IL (1) IL250394B (enExample)
WO (1) WO2016025401A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0102324A2 (de) * 1982-07-29 1984-03-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4619794A (en) * 1982-02-17 1986-10-28 Ciba-Geigy Corporation Spontaneous preparation of small unilamellar liposomes
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514755A1 (fr) 1981-10-21 1983-04-22 Rhone Poulenc Chim Base Procede de preparation de l'anhydride acetique
ZA831053B (en) * 1982-02-17 1985-03-27 Ciba Geigy Ag Lipids in aqueous phase
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH01274830A (ja) * 1988-04-28 1989-11-02 Asahi Denka Kogyo Kk 安全で且つ高度な界面活性を有する脂質組成物
JPH03127731A (ja) * 1989-10-12 1991-05-30 Yakult Honsha Co Ltd ビタミンｅの可溶化方法およびビタミンｅ製剤
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
EP2062574B1 (en) * 2006-09-08 2015-03-25 Kaneka Corporation Composition comprising reduced coenzyme q10 and lysolecithin
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619794A (en) * 1982-02-17 1986-10-28 Ciba-Geigy Corporation Spontaneous preparation of small unilamellar liposomes
EP0102324A2 (de) * 1982-07-29 1984-03-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs

Also Published As

Publication number Publication date
KR102507657B1 (ko) 2023-03-08
KR20220070551A (ko) 2022-05-31
IL250394A0 (en) 2017-03-30
IL250394B (en) 2021-05-31
KR20170033442A (ko) 2017-03-24
CA2956960C (en) 2023-10-24
EP3177279B1 (en) 2025-06-04
CN107072967B (zh) 2021-01-12
WO2016025401A1 (en) 2016-02-18
US9872908B2 (en) 2018-01-23
CN107072967A (zh) 2017-08-18
US11510985B2 (en) 2022-11-29
DK3177279T3 (da) 2025-08-18
AU2015301952A1 (en) 2017-02-16
EP3177279A1 (en) 2017-06-14
ES3033965T3 (en) 2025-08-11
JP6759203B2 (ja) 2020-09-23
CA2956960A1 (en) 2016-02-18
JP2017524036A (ja) 2017-08-24
US20180064813A1 (en) 2018-03-08
EP3177279A4 (en) 2018-04-18
US20200188518A1 (en) 2020-06-18
US20160166699A1 (en) 2016-06-16
US10463738B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
AU2016335287A1 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
US20080306137A1 (en) Pharmaceutical compositions comprising docetaxel and methods for preparation thereof
CA2948148C (en) Formulations of cyclophosphamide liquid concentrate
CN103189078A (zh) 含有透明质酸和l-精氨酸的抗粘连剂
KR20210105916A (ko) 우루소데옥시콜산을 함유하는 노시의 치료 또는 예방제
ES2946600T3 (es) Formulaciones líquidas de daptomicina
AU2015301952B2 (en) Oral composition for delivery of drugs and other substances
WO2017175098A1 (en) Stable liquid pharmaceutical formulations of bendamustine
US10918725B2 (en) Ophthalmic composition comprising rebamipide and method for preparing the same
JP5811421B2 (ja) 保存効力を示す非水性油性注射用製剤
KR101153250B1 (ko) 글리시리진 고농도 제제
KR20180132955A (ko) 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
JP2008189626A (ja) 経口用グリチルリチン可溶化製剤及びその製造方法
WO2009128357A1 (ja) 生理活性蛋白質含有ナノ粒子組成物およびその製造方法
RU2237478C2 (ru) Антимикробная фармацевтическая композиция
KR20140039663A (ko) 무복계면 멜록시캄 및 그 제조방법
ES2757060T3 (es) Composición que contiene apomorfina y un catión metálico divalente
KR20210104743A (ko) 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
KR20140046499A (ko) 무복계면 암포테리신 및 그 제조방법
KR20140043250A (ko) 무복계면 칼슘 및 그 제조방법
RO128701A2 (ro) Forme farmaceutice, semisolide, destinate administrării locale, conţinând asocieri de extracte atomizate de cynara scolymus, rosmarinus officinalis sp. şi hissopus officinalis sp.
KR20140043572A (ko) 무복계면 이트라코나졸 및 그 제조방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)